{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:02:04Z","timestamp":1791147724559,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic-Associated Steatotic Liver Disease (MASLD) is recognized as one of the most common chronic liver diseases in children globally, rising in tandem with the childhood obesity pandemic. Although high-income countries focus on advanced phenotyping, Sub-Saharan Africa (SSA) faces a distinct \u201ctwo-speed\u201d epidemic characterized by rapid urbanization and a unique \u201cdouble burden\u201d of malnutrition and obesity. This review examines the global and regional epidemiology of paediatric MASLD, contrasting established Western practices with the unique genetic, environmental, and diagnostic challenges of SSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted following the PRISMA-ScR guidelines and using the JBI methodological framework. PubMed\/MEDLINE, Embase, and African Journals Online (AJOL) were searched for literature published between 2010 and 2025 focusing on epidemiology, risk factors, and diagnostic performance in children aged 0\u201319 years. Evidence was synthesized to compare global prevalence patterns with emerging African data and to evaluate the validity of conventional screening approaches in resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 68 studies were included. Global evidence estimates paediatric MASLD prevalence between 7.6% and 14% in the general population and as high as 41% among children with obesity. In SSA, data remain sparse but alarming, with pooled prevalence among overweight children reaching 31.1%, a figure derived mostly from studies in the NAFLD-era utilizing ultrasound or ALT proxies, which may not align perfectly with newer MASLD criteria. The region exhibits a distinct \u201cAfrican Paradox\u201d with a lower frequency of the\n                      <jats:italic>PNPLA3<\/jats:italic>\n                      genetic risk variant (13.7%), which contributes to lower hepatic steatosis on imaging despite pronounced insulin resistance. As a result, reliance on alanine aminotransferase (ALT) and ultrasonography for screening risks under-detection, obscuring the metabolically high-risk yet hepatically lean phenotype common in SSA. Furthermore, environmental drivers such as high-fructose diets and endocrine-disrupting chemicals may be overriding genetic protection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Paediatric MASLD in SSA reflects a multifactorial pathology likely driven by environmental stressors, epigenetic \u201cthrifty phenotype\u201d programming, and rapid nutritional transition rather than simple caloric excess. Western-calibrated diagnostic algorithms are poorly suited to the African metabolic phenotype. To mitigate a future surge in advanced liver disease, public health strategy must prioritize low-cost innovations, including validating scalable markers such as Waist-to-Height Ratio (WHtR) and integrating task-shifting approaches within existing HIV and diabetes care platforms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1784970","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:24Z","timestamp":1773379524000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa"],"prefix":"10.3389","volume":"17","author":[{"given":"Bruno","family":"Basil","sequence":"first","affiliation":[{"name":"International Institute of Pathology and Forensic Science Research, David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peace Ngozi","family":"Okoro","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Umahi Federal University of Health Sciences","place":["Uburu, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e12849","DOI":"10.1111\/ijpo.12849","article-title":"Recent advances in the epidemiology of nonalcoholic fatty liver disease in children","volume":"16","author":"Shapiro","year":"2021","journal-title":"Pediatr Obes"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Zobair","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.020413","article-title":"Non-communicable diseases in sub-saharan africa: a scoping review of large cohort studies","volume":"9","author":"Goulart","year":"2019","journal-title":"J Glob Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e70137","DOI":"10.1002\/jgh3.70137","article-title":"Consensus statement on metabolic dysfunction-associated steatotic liver disease in children and adolescents from the joint TASL-TSPGHAN expert committee","volume":"9","author":"Lin","year":"2025","journal-title":"JGH Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082750","article-title":"Metabolic syndrome and liver disease: re-appraisal of screening, diagnosis, and treatment through the paradigm shift from NAFLD to MASLD","volume":"14","author":"Pecani","year":"2025","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12876-025-04314-y","article-title":"Global prevalence of metabolic dysfunction-associated fatty liver disease in children and adolescents with overweight and obesity: a systematic review and meta-analysis","volume":"25","author":"Jia","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2025.1506032","article-title":"Prevalence and risk factors of metabolic-associated fatty liver disease in sub-Saharan Africa: a systematic review and meta-analysis","volume":"4","author":"Sindato","year":"2025","journal-title":"Front Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1569972","article-title":"Editorial: Metabolic associated fatty liver disease (MAFLD) in childhood: a new challenge","volume":"16","author":"Munteanu","year":"2025","journal-title":"Front Endocrinol (Laus)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Paediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e186422","DOI":"10.1172\/JCI186422","article-title":"MASLD in children: integrating epidemiological trends with mechanistic and translational advances","volume":"135","author":"Schwimmer","year":"2025","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/nu16081124","article-title":"The interplay between endocrine-disrupting chemicals and the epigenome towards metabolic dysfunction-associated steatotic liver disease: a comprehensive review","volume":"16","author":"Nikolaou","year":"2024","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408398.2024.2392150","article-title":"Dietary fructose: from uric acid to a metabolic switch in Paediatric metabolic dysfunction-associated steatotic liver disease","volume":"2024","author":"Faienza","year":"2024","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000067","article-title":"Developmental origins of nonalcoholic fatty liver disease","volume":"17","author":"Wesolowski","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic risk factors for metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Pei","year":"2025","journal-title":"Gut Liver"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196216","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J Clin Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40842-024-00187-4","article-title":"From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions","volume":"10","author":"Basil","year":"2024","journal-title":"Clin Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"B18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction\u2013associated steatotic liver disease","volume":"80","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s13098-025-02031-w","article-title":"Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis","volume":"17","author":"Basil","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7235284","article-title":"Non-alcoholic fatty liver disease in Africa and Middle East: an attempt to predict the present and future implications on the healthcare system","volume":"2017","author":"Ahmed","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0307175","DOI":"10.1371\/journal.pone.0307175","article-title":"The dual burden of malnutrition and its associated factors among mother-child pairs at the household level in Ethiopia: an urgent public health issue demanding sector-wide collaboration","volume":"19","author":"Yigezu","year":"2024","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20085489","article-title":"Socio-economic inequalities in the double burden of malnutrition among under-five children: evidence from 10 selected Sub-Saharan African countries","volume":"20","author":"Alaba","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2022033","DOI":"10.29392\/001c.36904","article-title":"Addressing the double-burden of malnutrition among children and adolescents in sub-Saharan Africa","volume":"6","author":"Giancola","year":"2022","journal-title":"J Glob Health Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100728","article-title":"African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population","volume":"27","author":"Cavalcante","year":"2022","journal-title":"Ann Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i5.274","article-title":"Gender and racial differences in nonalcoholic fatty liver disease","volume":"6","author":"Pan","year":"2014","journal-title":"World J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e16123","DOI":"10.1111\/liv.16123","article-title":"Global epidemiological impact of PNPLA3 I148M on liver disease","volume":"45","author":"Kozlitina","year":"2025","journal-title":"Liver Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115164","article-title":"Polygenic risk score for metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a narrative review","volume":"26","author":"Kanda","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-pathmechdis-111523-023430","article-title":"Unraveling mechanisms of genetic risks in metabolic dysfunction-associated steatotic liver diseases: a pathway to precision medicine","volume":"20","author":"Zhang","year":"2025","journal-title":"Annu Rev Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00296-X","article-title":"Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa","volume":"6","author":"Spearman","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182010751","article-title":"Leveraging HIV care infrastructures for integrated chronic disease and pandemic management in sub-Saharan Africa","volume":"18","author":"Brault","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13513","DOI":"10.1111\/obr.13513","article-title":"Screening for metabolic complications of childhood and adolescent obesity: a scoping review of national and international guidelines","volume":"23","author":"Lim","year":"2022","journal-title":"Obes Rev"},{"key":"B33","article-title":"Overview of updated practice guidelines for Paediatric nonalcoholic fatty liver disease","volume":"14","author":"Shah","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/HMER.S533064","article-title":"Performance of APRI and FIB-4 scores compared to FibroScan: a cross-sectional study in a Black Sub-Saharan African population","volume":"17","author":"Nsumbu","year":"2025","journal-title":"Hepat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/jmri.29756","article-title":"MR and ultrasound for liver fat assessment in children: techniques and supporting evidence","volume":"62","author":"Serai","year":"2025","journal-title":"J Magn Reson Imag"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e6585","DOI":"10.1097\/MD.0000000000006585","article-title":"Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients","volume":"96","author":"Phisalprapa","year":"2017","journal-title":"Med (Balt)"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-09","article-title":"Scoping reviews","volume-title":"JBI Manual for Evidence Synthesis","author":"Peters","year":"2024"},{"key":"B38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","article-title":"Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988\u20131994 to 2007-2010","volume":"162","author":"Welsh","year":"2013","journal-title":"J Pediatr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1760","article-title":"Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016","volume":"5","author":"Arshad","year":"2021","journal-title":"Hepatol Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155919","article-title":"Obesity and dyslipidemia in early life: impact on cardiometabolic risk","volume":"156","author":"Zeljkovic","year":"2024","journal-title":"Metabolism"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e161971","DOI":"10.1001\/jamaPaediatrics.2016.1971","article-title":"Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease","volume":"170","author":"Newton","year":"2016","journal-title":"JAMA Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fradm.2024.1303375","article-title":"The prevalence of non-alcoholic fatty liver disease in Paediatric type 2 diabetes: a systematic review and meta-analysis","volume":"2","author":"Hu","year":"2024","journal-title":"Front Adolesc Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13098-023-01029-6","article-title":"Clinical and diagnostic characteristics of non-alcoholic fatty liver disease among Egyptian children and adolescents with type 1 diabetes","volume":"15","author":"Abdallah","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e001044","DOI":"10.1136\/bmjgast-2022-001044","article-title":"Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya","volume":"10","author":"Mburu","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.893579","article-title":"Prevalence and risk factors for hepatic steatosis in children with perinatal HIV on early antiretroviral therapy compared to HIV-exposed uninfected and HIV-unexposed children","volume":"10","author":"Rose","year":"2022","journal-title":"Front Pediatr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1017\/gheg.2019.2","article-title":"Non-alcoholic fatty liver disease in Africa: a hidden danger","volume":"4","author":"Paruk","year":"2019","journal-title":"Glob Health Epidemiol Genom"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e12759","DOI":"10.1111\/ijpo.12759","article-title":"The relationship between excessive dietary fructose consumption and paediatric fatty liver disease","volume":"16","author":"DiStefano","year":"2021","journal-title":"Pediatr Obes"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3345\/cep.2025.00157","article-title":"Metabolic dysfunction-associated steatotic liver disease in children: a practical update based on Indian Society of Paediatric Gastroenterology, Hepatology and Nutrition (ISPGHAN) 2024 guidelines","volume":"68","author":"Agrawal","year":"2025","journal-title":"Clin Exp Pediatr"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32510","article-title":"Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression","volume":"76","author":"Oliveira","year":"2022","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1818","article-title":"Risk of cardiovascular disease in individuals with nonobese nonalcoholic fatty liver disease","volume":"6","author":"Arvind","year":"2022","journal-title":"Hepatol Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1026901","article-title":"TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: a meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol (Laus)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3709-1","article-title":"DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum","volume":"27","author":"Bardai","year":"2016","journal-title":"Osteoporos Int"},{"key":"B54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40246-016-0083-1","article-title":"Mutation analysis of the COL1A1 and COL1A2 genes in Vietnamese patients with osteogenesis imperfecta","volume":"10","author":"Ho Duy","year":"2016","journal-title":"Hum Genomics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40246-017-0115-5","article-title":"Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients","volume":"11","author":"Zhytnik","year":"2017","journal-title":"Hum Genomics"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091346","article-title":"Genomics of wolfram syndrome 1 (WFS1)","volume":"13","author":"K\u00f5ks","year":"2023","journal-title":"Biomolecules"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1433060","article-title":"Novel WFS1 variants are associated with different diabetes phenotypes","volume":"15","author":"Wu","year":"2024","journal-title":"Front Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1185956","article-title":"The miR-668 binding site variant rs1046322 on WFS1 is associated with obesity in Southeast Asians","volume":"14","author":"Hammad","year":"2023","journal-title":"Front Endocrinol (Laus)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030536","article-title":"Genetic variants of HNF4A, WFS1, DUSP9, FTO, and ZFAND6 genes are associated with prediabetes susceptibility and inflammatory markers in the Saudi Arabian population","volume":"14","author":"Binjawhar","year":"2023","journal-title":"Genes (Basel)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.837116","article-title":"Performance of imaging techniques in non-invasive diagnosis of non-alcoholic fatty liver disease in children: a systematic review and meta-analysis","volume":"10","author":"Yu","year":"2022","journal-title":"Front Pediatr"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.24953\/turkjped.2016.05.009","article-title":"Waist to height ratio: a simple screening tool for nonalcoholic fatty liver disease in obese children","volume":"58","author":"\u00d6zhan","year":"2016","journal-title":"Turk J Pediatr"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-020-01192-w","article-title":"Paediatric obesity-related non-alcoholic fatty liver disease: waist-to-height ratio best anthropometrical predictor","volume":"90","author":"Umano","year":"2021","journal-title":"Pediatr Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3494-7","article-title":"The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease","volume":"60","author":"Mansoor","year":"2015","journal-title":"Dig Dis Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.885576","article-title":"Non-invasive diagnostic test for advanced fibrosis in adolescents with non-alcoholic fatty liver disease","volume":"10","author":"Mosca","year":"2022","journal-title":"Front Pediatr"},{"key":"B65","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1186\/s12887-024-05263-3","article-title":"Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Jin","year":"2024","journal-title":"BMC Pediatr"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00201","article-title":"Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease","volume":"9","author":"Lin","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316654","article-title":"Transcriptomics of MASLD pathobiology in african american patients in the washington DC area","volume":"24","author":"Mondal","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2024.24326","article-title":"Transcriptome-wide association study of metabolic dysfunction-associated steatotic liver disease identifies relevant gene signatures","volume":"36","author":"Wang","year":"2025","journal-title":"Turk J Gastroenterol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1784970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:26Z","timestamp":1773379526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1784970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":68,"alternative-id":["10.3389\/fendo.2026.1784970"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1784970","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1784970"}}